ArticleInternational journal of clinical and experimental pathology2015
TROP-1/Ep-CAM and CD24 are potential candidates for ovarian cancer therapy.
Article in International journal of clinical and experimental pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq.PloS one · 2018Article
- Identification of potential key genes associated with ovarian clear cell carcinoma.Cancer management and research · 2018Article
- Membranous CD24 expression as detected by the monoclonal antibody SWA11 is a prognostic marker in non-small cell lung cancer patients.BMC clinical pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To clarify the possible roles of epithelial cell adhesion molecule (TROP-1/Ep-CAM) and CD24 molecule (CD24) in ovarian tumorigenesis, and explore the possible mechanism underlying this disease. Recombinant eukaryotic expression vectors pCIneo-TROP-1/Ep-CAM and pCIneo-CD24 were transfected into human normal ovarian surface epithelia cell line IOSE-80 respectively, with IOSE-80 cells transfected with the empty vector pCIneo as control. MRNA and protein expression of TROP-1/Ep-CAM and CD24 were detected by RT-PCR and Western blotting, respectively. Cell migration was assayed by trans-well inserts; cell proliferation and adhesion were analyzed by CCK-8 Cell Counting kit; cell cycle and cell apoptosis analysis were performed by flow cytometer. The expressions of TROP-1/Ep-CAM and CD24 were obviously up-regulated in TROP-1/Ep-CAM group and CD24 group compared to that in control group (P<0.01). Cells of TROP-1/Ep-CAM group and CD24 group was significantly promoted migratory and proliferation abilities, but inhibited cell apoptosis and adhesive than that of control group (P<0.05). Besides, the number of the cells in G1 and G2 stages was significantly lower in two disease groups than that in control group (P<0.05). TROP-1/Ep-CAM and CD24 may play key roles in the progression of ovarian cancer through promoting migration, proliferation, inhibiting cell apoptosis and adhesion, and disturbing cell cycle. They may be used as specific therapeutic targets in the treatment of ovarian cancer. However, further experiments are still needed to confirm our results.
Indexed as
Identifiers
26191160PMC4503032W978140271What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.